NCT04731467 2024-12-27
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
Phase 1/2 Completed
Clinical Trials
11 trialsNCT02020707 2024-07-26
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
Phase 1 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT00404235 2018-10-16
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00833807 2015-11-26
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00110019 2015-10-19
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00081042 2013-12-19
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00255762 2013-10-28
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00288041 2013-03-05
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed